Cancer drug developer obtains $32.5M in private placement

05/3/2013 | American City Business Journals

Celator Pharmaceuticals, a New Jersey-based firm specializing in cancer drugs, secured $32.5 million in a private placement led by Valence Life Sciences. Proceeds will go toward the late-stage trial of CPX-351 liposome injection, the company's lead drug candidate for secondary acute myeloid leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA